DaVita
DVA
#1954
Rank
HK$77.98 B
Marketcap
HK$1,167
Share price
-0.77%
Change (1 day)
0.52%
Change (1 year)
DaVita Inc. is an American company providing dialysis services for patients with chronic and acute kidney failure.

P/E ratio for DaVita (DVA)

P/E ratio as of March 2026 (TTM): 14.7

According to DaVita's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.7065. At the end of 2024 the company had a P/E ratio of 13.6.

P/E ratio history for DaVita from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202413.6-1.51%
202313.810.25%
202212.51.86%
202112.3-32.76%
202018.230.72%
201913.9-77.24%
201861.3197.62%
201720.639.47%
201614.8-73.11%
201554.9147.85%
201422.15.37%
201321.05.73%
201219.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Universal Health Services
UHS
8.88-39.62%๐Ÿ‡บ๐Ÿ‡ธ USA
LabCorp
LH
25.9 76.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Tenet Healthcare
THC
13.8-6.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Pediatrix Medical Group
MD
10.4-28.98%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.